Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow SPRO
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
(7.38) | 31.52 | (7.20) | (9.55) |
Non Cash Items (Other) |
1.92 | 1.22 | 1.34 | 1.05 | |
Accounts Receivable Change |
23.59 | (24.49) | 25.36 | 0.00 | |
Accounts Payable Change |
0.62 | (0.70) | (0.48) | (0.06) | |
Change in payables and accrued liability |
1.08 | (2.23) | (2.44) | 2.97 | |
Income tax paid |
0.00 | 0.22 | (0.22) | 0.00 | |
Change in other assets and liabilities |
(2.40) | (13.89) | (0.50) | 0.24 | |
Operating Cash Flow |
17.42 | (8.35) | 15.86 | (5.35) | |
Investing cash flow |
— | — | — | — | |
Financing cash flow |
— | — | — | — | |
Change in Cash |
17.42 | (8.35) | 15.86 | (5.35) | |
Beginning Cash |
0.00 | 0.00 | 40.27 | 0.00 | |
Ending Cash |
17.42 | (8.35) | 56.13 | (5.35) | |
Stock Based Compensation |
1.05 | 1.01 | 1.11 | 0.82 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | — | |
Assets Liabilities Change (Total) |
22.89 | (41.09) | 21.73 | 3.15 |